Seropersistence of tick-borne encephalitis antibodies, safety and booster response to FSME-IMMUN® 0.5 ml in adults aged 18-67 years

Human Vaccines

Volumn 5, Issue 8, 2009, Pages 551-556

  Loew Baselli, Alexandra ^a   Poellabauer, Eva Maria ^a   Pavlova, Borislava G ^a   Fritsch, Sandor ^a   Koska, Manuela ^a   Bobrovsky, Roman ^a   Konior, Ryszard ^a,b   Ehrlich, Hartmut J ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

Author keywords

Adults; Booster; FSME IMMUN ; Immunogenicity; Seropersistence; TBE; Tick borne encephalitis; Vaccine

Indexed keywords

ANTIBODY; TICK BORNE ENCEPHALITIS ANTIBODY; TICK BORNE ENCEPHALITIS VACCINE; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE REACTION; MALE; MULTICENTER STUDY; PERSISTENT VIRUS INFECTION; PHASE 4 CLINICAL TRIAL; SEROPREVALENCE; SYSTEMIC DISEASE; TICK BORNE ENCEPHALITIS; TICK BORNE ENCEPHALITIS FLAVIVIRUS; VIRUS NEUTRALIZATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; ENCEPHALITIS VIRUSES, TICK-BORNE; ENCEPHALITIS, TICK-BORNE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNIZATION, SECONDARY; MIDDLE AGED; NEUTRALIZATION TESTS; POLAND; TIME FACTORS; VACCINATION; VIRAL VACCINES;

EID: 70349538822     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.8.8571     Document Type: Article

References (27)

1. Westway EG, Brinton MA, Gaidamovitch SY, Horzinek MC, Igarashi A, Kääriäinen L, et al. Flaviviridae. Intervirology 1985; 24:183-92.
2. Haglund M, Gunther G. Tick-borne encephalitis - pathogenesis, clinical course and long-term follow-up. Vaccine 2003; 21:11-8.
3. Randolph SE. Evidence that climate change has caused "emergence" of tick-borne diseases in Europe? Int J Med Microbiol 2004; 293:5-15.
4. Sumilo D, Bormane A, Asokliene L, Vasilenko V, Golovljova I, Avsic-Zupanc T, et al. Socio-economic factors in the differential upsurge of tick-borne encephalitis in Central and Eastern Europe. Rev Med Virol 2008; 18:81-95.
5. Süss J. Increasing prevalence of early summer meningoencephalitis in Europe. Deutsche Medizinische Wochenschrift (1946) 2005; 130:1397-400.
6. Kunze U. Tick-borne encephalitis: from epidemiology to vaccination recommendations in 2007. New issues-best practices. Wiener Medizinische Wochenschrift (1946) 2007; 157:228-32.
7. Kunze U. Tick-borne encephalitis - a European health challenge. Conference report of the 8th meeting of the International Scientific Working Group on Tick-borne Encephalitis (ISW TBE). Wiener Medizinische Wochenschrift (1946) 2006; 156:376-8.
8. Rendi-Wagner P. Risk and prevention of tick-borne encephalitis in travelers. J Travel Med 2004; 11:307-12.
9. Süss J. Tick-borne encephalitis in Europe and beyond - the epidemiological situation as of 2007. Eurosurveillance 2008; 13:18916. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18916 (accessed March 2009).
10. Barrett PN, Dorner F, Ehrlich HJ, S.A. P. Tick-borne encephalitis virus vaccine. In: S.A. P, ed. Vaccines. Philadelphia: Saunders & Elsevier 2004; 1039-55.
11. Süss J. Importance of tick-borne encephalitis (TBE) increases in Europe. Dtsch Med Wochenschr 2005; 130:1397-400.
12. Kunz C. Tick-borne encephalitis (Editorial). Vaccine 2003; 21:1-2.
13. Rendi-Wagner P, Kundi M, Zent O, Dvorak G, Jaehnig P, Holzmann H, et al. Persistence of protective immunity following vaccination against tick-borne encephalitis - longer than expected? Vaccine 2004; 22:2743-9.
14. Heinz FX, Holzmann H, Essl A, Kundi M. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 2007; 25:7559-67.
15. Kunz C. TBE vaccination and the Austrian experience. Vaccine 2003; 21:50-5.
16. Kunze M, Kunze U. Social marketing and the establishment of the ISW-TBE. Vaccine 2003; 21:62-5.
17. Fessl GFK. TBE vaccination in Austria: Results of a representative survey of the Austrian population. Fessel GFK Institute, Vienna, Austria 2006.
18. The International Scientific-Working Group on Tick-Borne Encephalitis (TBE/FSME). Epidemiology 2007. Reported Cases. http://www.isw-tbe.info (accessed March 2009).
19. Ehrlich HJ, Pavlova BG, Fritsch S, Poellabauer EM, Loew-Baselli A, Obermann-Slupetzky O, et al. Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity. Vaccine 2003; 22:217-23.
20. Loew-Baselli A, Fritsch S, Pavlova BG, Poellabauer EM, Harmacek P, Krammer M, et al. Safety and immunogenicity of FSME-Immun 'new' versus Encepur in adults. Int J Med Microbiol 2004; 293:128-9.
21. Loew-Baselli A, Konior R, Pavlova BG, Fritsch S, Poellabauer E, Maritsch F, et al. Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies. Vaccine 2006; 24:5256-63.
22. Kind A, Ritzmann P, Marty F, Zimmermann H. Tick-Borne-Encephalitis (TBE) Antibody Titers and Long Term Immunity. Z Allg Med 2008; 84:153-6.
23. Schöndorf I, Schönfeld C, Nicolay U, Zent O, Banzhoff A. Response to tick-borne encephalitis (TBE) booster vaccination after prolonged time intervals to primary immunization with the rapid schedule. Int J Med Microbiol 2006; 296:208-12.
24. Assessing adult vaccination status at age 50 years. MMWR Morb Mortal Wkly Rep 1995; 44:561-3.
25. Kießig ST, Abler U, Risse P, Friedrich J, Heinz F, Kunz C. Problems of cut-off level determination in enzyme immunoassays: the case of TBE-ELISA. Klin Lab 1993; 11:877-86.
26. Adner N, Leibl H, Enzersberger O, Kirgios M, Wahlberg T. Pharmacokinetics of human tick-borne encephalitis virus antibody levels after injection with human tick-borne encephalitis immunoglobulin, solvent/detergent treated, FSME-BULIN S/D in healthy volunteers. Scandinavian journal of infectious diseases 2001; 33:843-7.
27. Common Toxicity Criteria. Version 2.0. 1999. http://ctep.cancer.gov/ protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf; accessed on Dec 18, 2008.